Three Pots Stocks To Watch Out For, According to NASDAQ

gwpharma-logoAlthough the company isn’t yet profitable, GW claims some financial positives that most other marijuana stocks can’t. Thanks to Sativex, it has a solid revenue stream, generating over $46 million in the last 12 months. The company’s cash position also looks pretty good, with $234 million in cash and cash equivalents.

2. Insys Therapeutics Insys Therapeutics’ financial position looks even better than GW Pharmaceuticals, but not from any major contribution by marijuana-related products. The company made nearly $38 million in earnings last year on $222 million in revenue. Two drugs drive Insys’ financial performance currently.

Subsys, used for breakthrough cancer pain in opioid-tolerant patients, is by far the company’s biggest-selling product, accounting for over 99% of total revenue. Insys also sells generic Dronabinol SG, a second-line cannabinoid drug used for chemotherapy-induced nausea and vomiting and anorexia associated with weight loss in patients with AIDS.

Dronabinol SG isn’t making a big financial impact for Insys, but the company does have two other marijuana-based drugs in development that could one day be winners.

To read more, visit

Comments are closed.

Get the latest content first.
©Marijuana Stocks Report